Literature DB >> 27822631

Pancreatic Duct Involvement in Well-Differentiated Neuroendocrine Tumors is an Independent Poor Prognostic Factor.

Yoshihide Nanno1, Ippei Matsumoto2, Yoh Zen3, Kyoko Otani3, Jun Uemura4, Hirochika Toyama1, Sadaki Asari1, Tadahiro Goto1, Tetsuo Ajiki1, Keiichi Okano4, Yasuyuki Suzuki4, Yoshifumi Takeyama5, Takumi Fukumoto1, Yonson Ku1.   

Abstract

BACKGROUND: The biological behavior of well-differentiated neuroendocrine tumors of the pancreas (PNETs) is difficult to predict. This study was designed to determine whether involvement of the main pancreatic duct (MPD) serves as a poor prognostic factor for PNETs.
METHODS: The involvement of the MPD in PNETs was defined as ductal stenosis inside the tumor mass associated with distal MPDs more than twofold larger in diameter than the proximal ducts. We examined the correlation between MPD involvement and other clinicopathological parameters, including nodal metastasis and recurrence-free survival, in 101 patients treated consecutively at three referral centers in Japan. All patients underwent surgical resection.
RESULTS: MPD involvement was observed in 13 of the 101 cases (13%) and was associated with multiple unfavorable clinicopathological features (e.g., larger tumor size, higher histological grade, more frequent nodal metastasis, and higher recurrence rates). Patients with MPD involvement also showed significantly worse recurrence-free survival than did those without ductal involvement (P < 0.001), with a 5 years recurrence-free rate of 41%. On multivariate analysis, MPD involvement was significantly associated with nodal metastasis [odds ratio (OR) 16; 95% confidence interval (CI) 3.8-89; P < 0.001] and recurrence (OR 8.0; 95% CI 1.7-46; P = 0.009). The radiology-pathology correlation revealed that stenosis of the MPD was due to periductal and/or intraductal tumor invasion. Cases with MPD involvement had microscopic venous invasion (P = 0.010) and perineural infiltration (P = 0.002) more frequently than did those with no ductal infiltration.
CONCLUSIONS: MPD involvement in PNETs may serve as an imaging sign indicating an aggressive clinical course.

Entities:  

Mesh:

Year:  2016        PMID: 27822631     DOI: 10.1245/s10434-016-5663-8

Source DB:  PubMed          Journal:  Ann Surg Oncol        ISSN: 1068-9265            Impact factor:   5.344


  9 in total

Review 1.  Systematic Review and Metaanalysis of Lymph Node Metastases of Resected Pancreatic Neuroendocrine Tumors.

Authors:  Masayuki Tanaka; Max Heckler; André L Mihaljevic; Pascal Probst; Ulla Klaiber; Ulrike Heger; Simon Schimmack; Markus W Büchler; Thilo Hackert
Journal:  Ann Surg Oncol       Date:  2020-07-27       Impact factor: 5.344

Review 2.  Imaging of pancreatic neuroendocrine tumors: recent advances, current status, and controversies.

Authors:  Lingaku Lee; Tetsuhide Ito; Robert T Jensen
Journal:  Expert Rev Anticancer Ther       Date:  2018-07-17       Impact factor: 4.512

Review 3.  Prognostic and predictive factors on overall survival and surgical outcomes in pancreatic neuroendocrine tumors: recent advances and controversies.

Authors:  Lingaku Lee; Tetsuhide Ito; Robert T Jensen
Journal:  Expert Rev Anticancer Ther       Date:  2019-11-27       Impact factor: 4.512

Review 4.  Pancreatic neuroendocrine neoplasms: a 2022 update for radiologists.

Authors:  Samuel J Galgano; Ajaykumar C Morani; Dheeraj R Gopireddy; Kedar Sharbidre; David D B Bates; Ajit H Goenka; Hina Arif-Tiwari; Malak Itani; Amir Iravani; Sanaz Javadi; Silvana Faria; Chandana Lall; Emily Bergsland; Sadhna Verma; Isaac R Francis; Daniel M Halperin; Deyali Chatterjee; Priya Bhosale; Motoyo Yano
Journal:  Abdom Radiol (NY)       Date:  2022-03-04

5.  A New Preoperative Scoring System for Predicting Aggressiveness of Non-Functioning Pancreatic Neuroendocrine Neoplasms.

Authors:  Tetsuya Takikawa; Kazuhiro Kikuta; Shin Hamada; Kiyoshi Kume; Shin Miura; Naoki Yoshida; Yu Tanaka; Ryotaro Matsumoto; Mio Ikeda; Fumiya Kataoka; Akira Sasaki; Hidehiro Hayashi; Waku Hatta; Yohei Ogata; Kei Nakagawa; Michiaki Unno; Atsushi Masamune
Journal:  Diagnostics (Basel)       Date:  2022-02-03

6.  Pancreatic Neuroendocrine Neoplasm Invading the Entire Main Pancreatic Duct Diagnosed by a Preoperative Endoscopic Biopsy.

Authors:  Tomoya Kimura; Mitsuru Sugimoto; Tadayuki Takagi; Rei Suzuki; Naoki Konno; Hiroyuki Asama; Yuki Sato; Hiroki Irie; Jun Nakamura; Mika Takasumi; Minami Hashimoto; Tsunetaka Kato; Yasuhide Kofunato; Takashi Kimura; Shoki Yamada; Yuko Hashimoto; Shigeru Marubashi; Takuto Hikichi; Hiromasa Ohira
Journal:  Intern Med       Date:  2020-05-23       Impact factor: 1.271

Review 7.  What Are the Place and Modalities of Surgical Management for Pancreatic Neuroendocrine Neoplasms? A Narrative Review.

Authors:  Samuel Frey; Eric Mirallié; Maëlle Le Bras; Nicolas Regenet
Journal:  Cancers (Basel)       Date:  2021-11-26       Impact factor: 6.639

8.  Future Perspectives on Endoscopic Ultrasonography-Guided Therapy for Pancreatic Neoplasm.

Authors:  Woo Hyun Paik; Sang Hyub Lee; Sunguk Jang
Journal:  Clin Endosc       Date:  2018-05-18

9.  Clinical significance of the preoperative main pancreatic duct dilation and neutrophil-to-lymphocyte ratio in pancreatic neuroendocrine tumors (PNETs) of the head after curative resection.

Authors:  Bo Zhou; Canyang Zhan; Jie Xiang; Yuan Ding; Sheng Yan
Journal:  BMC Endocr Disord       Date:  2019-11-12       Impact factor: 2.763

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.